Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
Roche has signed a deal worth up to $2 billion with Atavistik Bio to discover new cardiometabolic drugs.
Atavistik Bio
Private
AI-enabled structure-based drug discovery company mapping allosteric binding sites on proteins and RNA to develop precision small molecule therapeutics.
Company Info
Sector:Small Molecule Pharma
Headquarters:Cambridge, Massachusetts, USA
Founded:2021
Website:atavistikbio.com/
Recent News
Leadership Team
Bryan E. Stuart
Chief Executive Officer
Marion Dorsch
President and Chief Scientific Officer
Paul Bruno
Chief Business Officer